clinical trials for glp-1 Timeline of discovery and development. (a) Key events in SGLTi and GLP-1 in HF

liraglutide, dulaglutide, semaglutide, versus control group

(Another DPP-4 inhibitor, vildagliptin, is widely prescribed in Europe but is not available in the U.S.) These agents are also available in combination with other diabetes medications (i.e., metformin, empagliflozin, pioglitazone, dapagliflozin, ertugliflozin)

Semaglutide produced 14.9 percent body weight loss over 68 weeks in the STEP 1 trial

No consultation required see which treatments are right for your goals in seconds

Overlapping two GLP-1 class drugs produces additive GI side effects that can be severe enough to require medical attention

You may also see improvements in: Blood pressure Cholesterol levels Inflammation markers Energy and sleep quality Why Long-Term Support Matters We believe in long-term weight loss treatment strategies that address the root causes of weight gain, not just the symptoms